Neurogen Corporation

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals Company

Bristol-myers Squibb Compnay

Janssen Pharmaceutica Nv

Dupont Pharmaceuticals, Inc.

Other

H. Lundbeck A/s

Norgine Bv

Jubilant Biosys Limited

Lundbeck, H., A/s

Rajagopal Bakthavatchalam

Paul Joseph Gilligan

James Peter Beck

Charles A Blum

Alan J Hutchison

Xiaozhang Zheng

Kevin J Hodgetts

Timothy M Caldwell

Robert J Chorvat

Richard Gerald Wilde

Harry Brielmann

Richard Eric Olson

Bertrand Leo Chenard

Stéphane De Lombaert

Andrew Y Thurkauf

Mark James Wall

Henricus Jacobus Maria Gijsen

Robert W DeSimone

Argyrios George Arvanitis

Taeyoung Yoon

Argyrios Georgios Arvanitis

Ishtiyaque Ahmad

Saravanan Vadivelu

Scott Michael Capitosti

Argyrios Georgious Arvanitis

Sivaramakrishna Battula

Jianjun Xu

Linda M Gustavson

Christopher M Flores

Gary Avonn Cain

James Beck

Manuka Ghosh

Parthasarathi Rajagopalan

Chandregowda Venkateshappa

Cheryl K Steenstra

Jun Yuan

James David Rodgers

Jiacheng Zhou

David Juergen Wustrow

John M Peterson

Hongbin Li

Christine M Tarby

Jennifer N Tran

Xiao-shu He

Mona Patel

Bheemashankar A Kulkarni

Paul E Aldrich

James William Darrow

Raghava Reddy Kethiri

Stephane De Lombaert

Marlys Hammond

Richard Louis Elliott

Scott Capitosti

Jianmin Mao

Lynette May Oh

Dario Doller

Carl Nicholas Hodge

Dhanalakshmi Sivanandhan

Zelda Rakowitz Wasserman

Yiping Shen

James E Krause

Qin Guo

Wallace C Pringle

St&eacute;phane De Lombaert

Alan J Hutchinson

Rohit Saxena

Barry L Johnson

Geoffrey White

Robert Scott Cheeseman

Stéphane DeLombaert

Helen Yin

Ajit Kumar Behera

Christopher Alexander Hewson

Sanjay Venkatachalapathi Kadnur

Sarkis Barret Kalindjian

Juluri Suresh

Vellarkad Viswanathan

Mohd Zainuddin

Akila Parvathy Dharshinis

Rajenda Kristam

Vellarkad Narayana Viswanadhan

Sanjeev Giri

Manas Kumar Basu

Scott M Capitosti

Henricus Jacobus Gijsen

David J Wustrow

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R, R, R, and G are defined herein.

Substituted imidazoles as N-type calcium channel blockers

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases. 

Substituted pyrimidine compounds, compositions and medicinal applications thereof

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD). 

Compounds useful as CCR9 modulators

5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. 

5-membered heterocyclic amides and related compounds

2-Phenoxy pyrimidinone analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

2-phenoxy pyrimidinone analogues

Substituted biaryl quinolin-4-ylamine analogues of Formula I are provided.  Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Substituted biaryl quinolin-4-ylamine analogues

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Biaryl piperazinyl-pyridine analogues

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Substituted quinolin-4-ylamine analogues

Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. 

Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies 

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues

Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof wherein Q, X, Y, Z, and RR, and R-Rare defined herein. These compounds are selective modulators of MCHreceptors that are, therefore, useful in the treatment of a variety of metabolic, feeding, and sexual disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also disclosed.

Melanin concentrating hormone receptor ligands

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. 

Substituted quinazolin-4-ylamine analogues

Growing community of inventors

Madison, CT, United States of America

Rajagopal Bakthavatchalam